CCCéline Chabanne

Céline Chabanne

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Céline Chabanne has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Invasive mold infection in heart transplant recipients: A nationwide multicenter matched case–control study between 2008 and 2022 in France

    by Baptiste Hoellinger, Eric Epailly, Fanny Vuotto, Valérie Letscher-Bru, Séverine Loridant, Céline Goeminne, Roxane Coelho, Guillaume Laurent, Soulef Guendouz, Giovanna Melica, et al.


  • Pulmonary Hypertension in Patients with Common Variable Immunodeficiency

    by Pierre Thoré, Xavier Jaïs, Laurent Savale, Peter Dorfmuller, Athénaïs Boucly, Matthieu Devilder, Olivier Meyrignac, Jérémie Pichon, Julie Mankikian, Marianne Riou, et al.

    Purpose Common variable immunodeficiency (CVID) is known to cause infectious, inflammatory, and autoimmune manifestations. Pulmonary hypertension (PH) is an unusual complication of CVID with largely unknown characteristics and mechanisms. Methods We report the clinical, functional, hemodynamics, radiologic and histologic characteristics, and outcomes of CVID-associated PH patients from the French PH Network. Results Ten patients were identified. The median (range) age at CVID diagnosis was 36.5 (4–49) years and the median delay between CVID and PH diagnosis was 12 (0–30) years. CVID-associated PH affected predominantly women (female-to-male ratio 9:1). Most patients were New York Heart Association functional class III with a severe hemodynamic profile and frequent portal hypertension (n = 6). Pulmonary function tests were almost normal in 70% of patients and showed a mild restrictive syndrome in 30% of patients while the diffusing capacity for carbon monoxide was decreased in all but one patient. High-resolution computed tomography found enlarged mediastinal nodes, mild interstitial infiltration with reticulations and nodules. Two patients had a CIVD-interstitial lung disease, and one presented with bronchiectasis. Pathologic assessment of lymph nodes performed in 5 patients revealed the presence of granulomas (n = 5) and follicular lymphoid hyperplasia (n = 3). At last follow-up (median 24.5 months), 9 patients were alive, and one patient died of Hodgkin disease. Conclusion PH is a possible complication of CVID whose pathophysiological mechanisms, while still unclear, would be due to the inflammatory nature of CVID. CVID-associated PH presents as precapillary PH with multiple possible causes, acting in concert in some patients: a portal hypertension, a pulmonary vascular remodeling, sometimes a pulmonary parenchymal involvement and occasionally an extrinsic compression by mediastinal lymphadenopathies, which would be consistent with its classification in group 5 of the current PH classification.


  • Trithérapie initiale dans l’hypertension artérielle pulmonaire

    by A. Baron, A. Boucly, L. Savale, X. Jaïs, F. Picard, V. Cottin, E. Bergot, C. Dauphin, A. Bourdin, A. Chaouat, et al.

  • Phénotype clinique et évolution des patients atteints d’HTAP héritable présentant une mutation du gène TBX4

    by P. Thoré, B. Girerd, X. Jaïs, S. Laurent, M. Eyries, M. Levy, C. Ovaert, A. Servettaz, A. Guillaumot, C. Dauphin, et al.

  • Open Access

    Three-year haemodynamic performance of the St Jude Trifecta bioprosthesis

    by Vito Giovanni Ruggieri, Amedeo Anselmi, Celine Chabanne, Bernard Lelong, Erwan Flecher, Jean-Philippe Verhoye, Alain Leguerrier

    OBJECTIVES To examine the haemodynamic performance of the St Jude Trifecta valve for aortic valve replacement (AVR) at 3 years after implantation. METHODS In a single-centre, prospective, observational, independent study, we enrolled 122 patients who had AVR using a Trifecta bioprosthesis in the July 2010–June 2011 period. A clinical and echocardiographic in-house follow-up was scheduled. RESULTS In our series, 14.7% of patients received a 19-mm, 28.7% had a 21-mm, 35.2% had a 23-mm and 21.3% had a greater-size prosthesis. There were no cases of operative mortality or of valve-related complications both early and at follow-up (except one sudden unexplained death). Completeness of the 3-year echocardiographic follow-up was 80% among survivors. The average mean transvalvular gradient (mTVG) at 3 years was 14.2, 10.8, 8.6, 7.1 and 6.8 mmHg (sizes 19 to 27/29, respectively). There was no statistically significant difference between average mTVGs measured immediately after implantation versus at the 3-year follow-up in the overall population. The average peak transvalvular gradient (pTVG) at 3 years was 25, 20, 16.8, 13.9 and 14.4 mmHg (sizes 19 to 27/29, respectively). The average indexed effective orifice area (iEOA) at 3 years was 0.8, 0.9, 1, 1.3 and 1.3 cm2/m2 (sizes 19–27, respectively). The rate of moderate patient–prosthesis mismatch (PPM) at 3 years was 15.7%; there were two instances of severe PPM (2.2%). All cases of PPM occurred in the 19, 21 and 23 mm size subgroups. CONCLUSIONS The Trifecta valve retains its excellent haemodynamic properties at the 3-year follow-up. The rate of PPM is considerably low.